EU Gives OK for Teva to Buy Allergan Generics

As mooted earlier in the week, the European Commission (EC) has given its approval for Israel-based Teva’s planned $40.5 billion acquisition of the generics arm of Ireland-domiciled Allergan.

Strings attached to the deal stipulate that the company divest certain assets, including the bulk of both merger partners’ generics businesses in the UK and Ireland and Teva’s generics portfolio in Iceland.

Separately, the generics company’s parent, Allergan, is merging with Pfizer in a $150 billion transaction that sees the Dublin-based drugmaker officially taking over the US pharmaceuticals giant.

Following “a thorough market investigation,” in which the Commission said it assessed whether the combination of the two companies’ generics assets would affect competition in some European Economic Area (EEA) countries beyond the markets for individual molecules, the EU antitrust body said it found concerns in the three countries mentioned, where Teva and Allergan were the market leaders.

If Teva’s bid wins approval of regulatory authorities in other markets, the deal, the largest in Israel's corporate history, will give the Israeli drugmaker – already a generics powerhouse – greater economies of scale, boosting its profitability in the low-margin generic drugs business.

The combined company would have pro forma revenues of $26 billion and EBITDA of $9.5 billion in 2016. Teva said it expected cost synergies and tax savings of $1.4 billion annually by the third anniversary of the transaction.

US say antitrust approval is still out and reports say approval by the US Federal Trade Commission – even with divestments – may be harder to obtain.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.